NLCQ-1 (NSC 709257): Exploiting Hypoxia with a Weak DNA-Intercalating Bioreductive Drug

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5714-5720

  Papadopoulou, Maria V ^a,b   Bloomer, William D ^a  

^a Evanston Northwestern Healthcare ^*  (United States)

^b EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BIOREDUCTIVE DRUG; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIN; FLUOROURACIL; INTERCALATING AGENT; MELPHALAN; NSC 709257; PACLITAXEL; PRODRUG; QUINOLINE DERIVATIVE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW TOXICITY; CANCER; CANCER MODEL; CANCER RADIOTHERAPY; CELL LINE; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG DNA BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EYE TOXICITY; HUMAN; HUMAN CELL; HYPOXIA; INTERCALATION COMPLEX; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RAT; RETINA DISEASE; REVIEW; SCALE UP; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; IMIDAZOLES; INTERCALATING AGENTS; NEOPLASMS; QUINOLINES; RADIOIMMUNOTHERAPY;

EID: 0344629821     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Hockel, M., Schlenger, K., Mitze, M., Schaffer, U., and Vaupel, P. Hypoxia and radiation response in human tumors. Seminars in Radiat. Oncol., 6: 3-9, 1996.
2. Siemann, D. W. Modification of chemotherapy by nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys., 10: 1585-1594, 1984.
3. Grau, C., and Overgaard, J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother. Oncol., 13: 301-309, 1988.
4. Brown, J. M. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med. Today. 6: 157-162, 2000.
5. Cuvier, C., Jang, A., and Hill, R. P. Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin. Exp. Metastasis, 15: 19-25, 1997.
6. Graham, C. H., Forsdike, J., Fitzgerald, C. J., MacDonald-Goodfellow, S. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int. J. Cancer, 80: 617-623, 1999.
7. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of uterine cervix. Cancer Res., 56: 4509-4515, 1996.
8. Stratford, I. J., and Workman, P. Bioreductive drugs into the next millennium. Anticancer Drug Des., 13: 519-528, 1998.
9. Denny, W. A. Prodrug strategies in cancer therapy. Eur. J. Med. Chem., 36: 577-595, 2001.
10. Rockwell, S., Sartorelli, A. C., Tomasz, M., and Kennedy, K. A. Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Rev., 12: 165-176, 1993.
11. Brown, M. J., and Lemmon, M. J. Potentiation by the hypoxic cytotoxin SR4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 50: 7745-7749, 1990.
12. Roberts, P. B., Denny, W. A., Wakelin, L. P. G., Anderson, R. F., and Wilson, W. R. Radiosensitization of mammalian cells in vitro by nitroacridines. Radiat. Res., 123: 153-164, 1990.
13. Langmuir, V. K., Rooker, J. A., Osen, M., Mendonca, H. L., and Laderoute, K. R. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res., 54: 2845-2847, 1994.
14. Siemann, D. W. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiother. Oncol., 34: 47-53, 1995.
15. Papadopoulou, M. V., Ji, M., and Bloomer, W. D. THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo, 10: 49-58, 1996.
16. Papadopoulou, M. V., Ji, M., Rao, M. K., and Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol. Res., 8: 425-434, 1996.
17. Papadopoulou, M. V., Ji, M., Rao, M. K., and Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): A novel DNA-affinic bioreductive agent as chemosensitizer. I. Oncol. Res., 9: 249-257, 1997.
18. Dorie, M. J., and Brown, J. M. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother. Pharmacol., 39: 361-366, 1997.
19. Gallagher, R., Hughes, C. M., Murray, M. M., Friery, O. P., Patterson, L. H., Hirst, D. G., McKeown, S. R. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br. J. Cancer, 85: 625-629, 2001.
20. Haffty, B. G., Son, Y. H., Wilson, L. D., Papac, R., Fischer, D., Rockwell, S. Sartorelli, A. C., Ross, D., Sasaki, C. T., and Fischer, J. J. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Radiat. Oncol. Investig., 5: 235-245, 1997.
21. Lee, D-J., Trotti, A., Spencer, S., Rostock, R., Fisher, C., von Roemeling, R., Harvey, E., and Groves, E. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. Int. J. Radiat. Oncol. Biol. Phys., 42: 811-815, 1998.
22. Miller, V. A., Ng, K. K., Grant, S. C., Kindler, H., Pizzo, B., Heelan, R. T., von Roemeling, R., and Kris, M. G. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol., 8: 1269-1271, 1997.
23. Treat, J., Johnson, E., Langer, C., Belani, C., Haynes, B., Greenberg, R., Rodriquez, R., Drobins, P., Miller, W. Jr., Meehan, L., McKeon, A., Devin, J., von Roemeling, R., and Viallet, J. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol., 16: 3524-3527, 1998.
24. von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P., Talbot, D., Rey, A., Butler, T. W., Hirsh, V., Olver, I., Bergman, B., Ayoub, J., Richardson, G., Dunlop, D., Arcenas, A., Vescio, R., Viallet, J., and Treat, J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. J. Clin. Oncol., 18: 1351-1359, 2000.
25. Panicucci, R., Heal, R., Laderonte, K., Cowan, D., McClelland, R. A., and Rauth, A. M. NLP-1: A DNA intercalating hypoxic cell radiosensitizer and cytotoxin. Int. J. Radiat. Oncol. Biol. Phys., 16: 1039-1043, 1989.
26. Papadopoulou, M. V., Epperly, M. W., Shields, D. S., and Bloomer, W. D. Radiosensitization and hypoxic cell toxicity of NLA-1 and NLA-2, two new bioreductive compounds. Jpn. J. Cancer Res., 83: 410-414, 1992.
27. Denny, W. A., Roberts, P. B., Anderson, R. F., Brown, J. M., Phil, D., and Wilson, W. R. NLA-1: A 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. Int. J. Radiat. Oncol. Biol. Phys., 22: 553-556, 1992.
28. Wilson, W. R., Denny, W. A., Stewart, G. M., Fenn, A., and Probert, J. C. Reductive metabolism and hypoxia-selective toxicity of nitracrine. Int. J. Radiat. Oncol. Biol. Phys., 12: 1235-1238, 1986.
29. Denny, W. A., Roos, I. A. G., and Wakelin, L. P. G. Interactions between antitumor activity, DNA breakage, and DNA binding kinetics for 9-aminoacridinecarboxamide antitumor agents. Anticancer drug design, 1: 141-147, 1986.
30. Zwelling, L. DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Metast. Rev., 4: 263-276. 1985.
31. Rosenzweig, H. S., Papadopoulou, M. V., and Bloomer, W. D. A study of the interaction of NLA-compounds with topoisomerases I and II. Proc. Am. Assoc. Cancer Res. Annu. Meet., 35: 362, 1994.
32. Papadopoulou. M. V., Rosenzweig, H. S., Doddi, M., and Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)-propylamino]-1, 2, 3, 4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol. Res., 6: 439-448, 1994.
33. Papadopoulou, M. V., Ji, M., Rao, M. K., and Bloomer, W. D. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol. Res., 12: 185-192, 2000.
34. O'Brien, R. L., and Hahn, F. E. Chloroquine structural requirements for binding to deoxyribonucleic acid and antimalarial activity. Antimicrob. Agents Chemother., 315-320, 1965.
35. Reid, J. M., Squillace, D. P., and Ames. M. M. Single dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 Mice. Cancer Chem. Pharmacol., 51: 483-487, 2003.
36. McClelland, R. A., Panicucci, R., and Rauth, A. M. Products of the reduction of 2-nitroimidazoles. J. Am. Chem. Soc., 109: 4308-4313, 1987.
37. Noss, M. B., Panicucci, R., McClelland, R. A., and Rauth, A. M. Preparation, toxicity and mutagenicity of 1-methyl-2-nitrosoimidazole: a toxic 2-nitroimidazole reduction product. Biochem. Pharmacol., 37: 2585-2593, 1988.
38. Workman, P. Keynote address: bioreductive mechanisms. Int. J. Radiat. Oncol. Biol. Phys., 22: 631-637, 1992.
39. Papadopoulou, M. V., Ji, M., Rao, M. K., and Bloomer, W. D. Reductive activation of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol. Res. 14: 21-29, 2003.
40. Tomigahara, Y., Onogi, M., Saito, K., Isobe, N., Kaneko, H., and Nakatsuka, I. Metabolism of cyanox in rat. II. Sex-related differences in oxidative dearylation and disulphuration. Xenobiotica, 30: 395-406, 2000.
41. Papadopoulou, M. V., Ji, M., and Bloomer, W. D. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int. J. Radiat. Oncol. Biol. Phys., 42: 775-779, 1998.
42. Papadopoulou, M. V., Ji, M., Rao, M. K., and Bloomer, W. D. 4-[3-(2-Nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent as radiosensitizer in vitro and in vivo. Comparison with tirapazamine. Oncol. Res., 12: 325-333, 2000.
43. Papadopoulou, M. V., Ji, M., Ji, X., Bloomer, W. D., and Hollingshead, M. G. Therapeutic advantage from combining Paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Cancer Chem. Pharmacol., 50: 501-508, 2002.
44. Papadopoulou, M. V., Ji. M., Bloomer, W. D., Hollingshead, M. G. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts. J. Exp. Ther. Oncol., 2: 298-305, 2002.
45. Papadopoulou, M. V., Ji, M., Ji, X., and Bloomer. W. D. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo., Comparison with tirapazamine. Cancer Chem. Pharmacol., 50: 291-298, 2002.
46. Papadopoulou, M. V., Ji, M., Ji, X., and Bloomer. W. D. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-I 1, in vivo. Comparison with tirapazamine. Oncol. Res., 13: 47-54, 2002.
47. Papadopoulou, M. V., Ji, M., and Bloomer, W. D. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother. Pharmacol., 48: 160-168, 2001.
48. Papadopoulou, M. V., Ji, X., and Bloomer, W. D. Hypoxia-dependent retinal toxicity of NLCQ-1 and tirapazamine in BALB/c mice. Proc. Am. Assoc. Cancer Res. Annu. Meet., 43: 1092, 2002.
49. Lee, A. E., and Wilson, W. R. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol. Appl. Pharmacol., 163: 50-59, 2000.
50. Blumenthal, R. D., Taylor, A., Osorio, L., Ochakovskaya, R., Raleigh, J., Papadopoulou, M., Bloomer, W. D., and Goldenberg, D. M. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int. J. Cancer, 94: 564-571, 2001.
51. Papadopoulou, M. V., Ji, X., Xue, C., and Bloomer, W. D. In vitro schedule-dependent potentiation of taxol, 5FU and cisDDP by the hypoxic cytotoxin NLCQ-1. Comparison with tirapazamine. In: The 11th International Conference on Chemical Modifiers of Cancer Treatment. Tumor Physiology and Cancer Treatment, October 5-7, 2000, Banff, Alberta, Canada.
52. Papadopoulou, M. V., Xue, C., and Bloomer, W. D. The involvement of DNA repair genes in the hypoxia-dependent NLCQ-1 (NSC 709257) toxicity and its synergistic interaction with cisplatin or melphalan. In: The 12th International Congress of Radiation Research, August 17-22, 2003, Brisbane, Australia.
53. Papadopoulou, M. V., Ji, X., Bloomer, W. D. Mechanisms involved in the potentiation of paclitaxel or 5-FU by the hypoxic cytotoxin NLCQ-1. Clin. Cancer Res., 7 (Suppl.): 3679, 2001.